Experimental cell therapy tested in men with untreatable prostate cancer

NCT ID NCT07344311

Summary

This is the first human study of an experimental cell therapy called A-CAR032 for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. The trial will test the safety of different doses and see if the therapy can shrink tumors. It is for patients who have already tried other treatments and have limited options.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Cancer Hospital

    NOT_YET_RECRUITING

    Beijing, Beijing Municipality, 100142, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Affiliated Hospital of Xuzhou Medical University

    NOT_YET_RECRUITING

    Xuzhou, Jiangsu, 221006, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Wenzhou Medical University

    NOT_YET_RECRUITING

    Wenzhou, Zhejiang, 325000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310013, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Tongji Hospital, Tongji Medical College of HUST

    NOT_YET_RECRUITING

    Wuhan, Hubei, 430100, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.